Tareq Abadl: Irradiated Blood – Safer, Not More Dangerous
Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, shared a post on LinkedIn:
“Irradiated Blood – Safer, Not More Dangerous.
Did you know that some blood units are actually irradiated before transfusion… not to harm, but to protect the patient?
What Does ‘Irradiated Blood’ Mean?
When we say a blood unit is irradiated, it means it has been exposed to controlled radiation to inactivate donor T lymphocytes.
Important:
Nothing ‘toxic’ is added to the blood — this is purely a safety modification.
Why Is Irradiation Needed?
The goal is to prevent a rare but serious complication:
Transfusion-Associated Graft-Versus-Host Disease (TA-GVHD)
This happens when:
- Viable donor T cells attack the recipient’s tissues
- Leading to severe, often fatal immune reactions
According to the AABB, irradiation is used to stop donor T cells from proliferating, eliminating this risk.
Which Blood Components Are Irradiated?
Irradiation is mainly used for cellular components, such as:
- Red Blood Cells (RBCs)
- Platelets
Plasma is not irradiated (it doesn’t contain viable lymphocytes).
Beyond ABO and Rh – Smarter Blood Banking
Modern transfusion medicine is not just about matching blood groups:
Blood banks also select specialized products based on patient needs, including:
- Irradiated components
- Washed red cells
- CMV-seronegative units
As highlighted by Canadian Blood Services, these modifications help reduce transfusion-related risks in specific clinical situations.
Does Irradiation Affect the Blood Itself?
Yes – and this is clinically important:
- Reduced shelf life
- Increased potassium levels
- Structural/biochemical changes in cells
Recent updates from AABB emphasize that irradiated products are used only when clearly indicated because of these effects.
Bottom Line
Irradiated blood is not ‘dangerous blood’ – it’s safer blood for the right patient.
In transfusion medicine:
It’s not just about giving blood…
It’s about giving the right product, to the right patient, at the right time.”

Other posts featuring Tareq Abadl on Hemostasis Today.
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026
-
Jul 14, 2026, 12:02Louise St. Germain Bannon: Our first ISTH regulatory session at ISTH 2026
-
Jul 14, 2026, 11:21Malwina Maliszewska: Advancing Coagulation Diagnostics at ISTH 2026
-
Jul 14, 2026, 11:07Mary Cushman: Honoring Outstanding Mentorship at ISTH 2026
-
Jul 14, 2026, 10:53Maha Othman: Advancing the Management of Inherited Thrombocytopenias at ISTH 2026
-
Jul 14, 2026, 10:24Sara Zalghout: The Little Things That Make ISTH 2026 Special
-
Jul 14, 2026, 10:11Joseph R. Shaw: GAUGE Advances FXa Inhibitor Reversal at ISTH 2026
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation